Last reviewed · How we verify
Autologous Cytokine Rich Serum
Autologous Cytokine Rich Serum is a Biologic drug developed by Corporacion Parc Tauli. It is currently in Phase 1 development.
At a glance
| Generic name | Autologous Cytokine Rich Serum |
|---|---|
| Sponsor | Corporacion Parc Tauli |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS) (NA)
- Arthroscopic Debridement Versus Autologous Cytokine Rich Serum for the Treatment of Lateral Epicondylitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous Cytokine Rich Serum CI brief — competitive landscape report
- Autologous Cytokine Rich Serum updates RSS · CI watch RSS
- Corporacion Parc Tauli portfolio CI
Frequently asked questions about Autologous Cytokine Rich Serum
What is Autologous Cytokine Rich Serum?
Autologous Cytokine Rich Serum is a Biologic drug developed by Corporacion Parc Tauli.
Who makes Autologous Cytokine Rich Serum?
Autologous Cytokine Rich Serum is developed by Corporacion Parc Tauli (see full Corporacion Parc Tauli pipeline at /company/corporacion-parc-tauli).
What development phase is Autologous Cytokine Rich Serum in?
Autologous Cytokine Rich Serum is in Phase 1.